Top

Archives of Gynecology and Obstetrics

Published in:

01-03-2020 | Fenoterol | Maternal-Fetal Medicine

Antenatal exposure to fenoterol is not associated with the development of retinopathy of prematurity in infants born before 32 weeks of gestation

Authors: Hannes Hudalla, Thomas Bruckner, Johannes Pöschl, Thomas Strowitzki, Ruben-J. Kuon

Published in: Archives of Gynecology and Obstetrics | Issue 3/2020

Abstract

Purpose

Despite safety concerns, β₂-sympathomimetics are still widely used as tocolytic agents. β-Blockers in turn are used to treat vasculo-proliferative diseases of the newborn such as retinopathy of prematurity (ROP), which may lead to visual impairment and blindness. The scope of this study was to investigate whether antenatal exposure to the β₂-sympathomimetic fenoterol contributes to the development of ROP.

Methods

For this single-center retrospective case–control study of prospectively collected clinical data, all infants born before 32 weeks of gestation between 2001 and 2012 were included. The association of prenatal exposure to fenoterol and the development of ROP were analyzed by multivariate logistic regression.

Results

n = 1134 infants < 32 weeks of gestation were screened for eligibility, out of which n = 722 met the inclusion criteria. Exposure to fenoterol (n = 505) was not associated with a higher rate of ROP (OR 0.721, 95% CI 0.463–1.122). Further, duration of exposure (days) did not alter the incidence of ROP (OR 1.001, 95% CI 0.986–1.016). Frequency distribution of different ROP stages and the need for therapeutic intervention was also not affected by prenatal exposure to fenoterol. Risk factors for the development of ROP like low birth weight, low gestational age, prolonged respiratory support and multiple gestation were confirmed in our large study cohort.

Conclusion

β₂-Sympathomimetic tocolysis does not increase the rate of ROP in premature infants born < 32 weeks of gestation. Our results render fenoterol a safe tocolytic agent regarding neonatal ROP development.

Available only for authorised users

Murray CJL, Vos T, Lozano R et al (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet 380:2197–2223. https://doi.org/10.1016/S0140-6736(12)61689-4 CrossRefPubMed

Haas DM, Caldwell DM, Kirkpatrick P et al (2012) Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ 345:e6226. https://doi.org/10.1136/bmj.e6226 CrossRefPubMedPubMedCentral

Haas DM, Imperiale TF, Kirkpatrick PR et al (2009) Tocolytic therapy: a meta-analysis and decision analysis. Obstet Gynecol 113:585–594. https://doi.org/10.1097/AOG.0b013e318199924a CrossRefPubMed

de Heus R, Mol BW, Erwich J-JHM et al (2009) Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. BMJ 338:b744–b744. https://doi.org/10.1136/bmj.b744 CrossRefPubMedPubMedCentral

Neilson JP, West HM, Dowswell T (2014) Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 6: CD004352. https://doi.org/10.1002/14651858.CD004352.pub3

Tolsma KW, Allred EN, Chen ML et al (2011) Neonatal bacteremia and retinopathy of prematurity: the ELGAN study. Arch Ophthalmol 129:1555–1563. https://doi.org/10.1001/archophthalmol.2011.319 CrossRefPubMed

Kuon RJ, Hudalla H, Seitz C et al (2015) Impaired neonatal outcome after emergency cerclage adds controversy to prolongation of pregnancy. PLoS ONE 10:e0129104. https://doi.org/10.1371/journal.pone.0129104 CrossRefPubMedPubMedCentral

Dammann O, Brinkhaus M-J, Bartels DB et al (2009) Immaturity, perinatal inflammation, and retinopathy of prematurity: a multi-hit hypothesis. Early Hum Dev 85:325–329. https://doi.org/10.1016/j.earlhumdev.2008.12.010 CrossRefPubMed

Hartnett ME, Penn JS (2012) Mechanisms and management of retinopathy of prematurity. N Engl J Med 367:2515–2526. https://doi.org/10.1056/NEJMra1208129 CrossRefPubMedPubMedCentral

10.

Aiello LP, Pierce EA, Foley ED et al (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci 92:10457–10461. https://doi.org/10.1073/pnas.92.23.10457 CrossRefPubMed

11.

International committee for the classification of retinopathy of prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991–999. https://doi.org/10.1001/archopht.123.7.991 CrossRef

12.

Lundgren P, Kistner A, Andersson EM et al (2014) Low birth weight is a risk factor for severe retinopathy of prematurity depending on gestational age. PLoS ONE 9:e109460. https://doi.org/10.1371/journal.pone.0109460 CrossRefPubMedPubMedCentral

13.

Razak A, Faden M (2019) Association of small for gestational age with retinopathy of prematurity: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed fetal neonatal-2019-316976. https://doi.org/10.1136/archdischild-2019-316976

14.

York JR, Landers S, Kirby RS et al (2004) Arterial oxygen fluctuation and retinopathy of prematurity in very-low-birth-weight infants. J Perinatol 24:82–87. https://doi.org/10.1038/sj.jp.7211040 CrossRefPubMed

15.

Askie LM, Darlow BA, Finer N et al (2018) Association between oxygen saturation targeting and death or disability in extremely preterm infants in the neonatal oxygenation prospective meta-analysis collaboration. JAMA 319:2190–2201. https://doi.org/10.1001/jama.2018.5725 CrossRefPubMedPubMedCentral

16.

Slidsborg C, Jensen A, Forman JL et al (2016) Neonatal risk factors for treatment-demanding retinopathy of prematurity: a danish national study. Ophthalmology 123:796–803. https://doi.org/10.1016/j.ophtha.2015.12.019 CrossRefPubMed

17.

Natarajan G, Shankaran S, Nolen TL et al (2019) Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment. Pediatrics 144:e20183537. https://doi.org/10.1542/peds.2018-3537 CrossRefPubMedPubMedCentral

18.

Solebo AL, Teoh L, Rahi J (2017) Epidemiology of blindness in children. Arch Dis Child 102:853–857. https://doi.org/10.1136/archdischild-2016-310532 CrossRefPubMed

19.

Sankar MJ, Sankar J, Chandra P (2018) Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev 1:CD009734. https://doi.org/10.1002/14651858.CD009734.pub3

20.

Kaempfen S, Neumann RP, Jost K, Schulzke SM (2018) Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev 3: CD011893. https://doi.org/10.1002/14651858.CD011893.pub2

21.

Zhang L, Mai H-M, Zheng J et al (2014) Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. Int J Clin Exp Pathol 7:48–55PubMed

22.

Novoa M, Baselga E, Beltran S, et al (2018) Interventions for infantile haemangiomas of the skin. Cochrane Database Syst Rev 4: CD006545. https://doi.org/10.1002/14651858.CD006545.pub3

23.

Léauté-Labrèze C, Harper JI, Hoeger PH (2017) Infantile haemangioma. Lancet 390:85–94. https://doi.org/10.1016/S0140-6736(16)00645-0 CrossRefPubMed

24.

Garg J, Feng Y-X, Jansen SR et al (2017) Catecholamines facilitate VEGF-dependent angiogenesis via β2-adrenoceptor-induced Epac1 and PKA activation. Oncotarget 8:44732–44748. https://doi.org/10.18632/oncotarget.17267 CrossRefPubMedPubMedCentral

25.

Mayer M, Minichmayr A, Klement F et al (2013) Tocolysis with the β-2-sympathomimetic hexoprenaline increases occurrence of infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed 98:F108–F111. https://doi.org/10.1136/archdischild-2011-301030 CrossRefPubMed

26.

Hudalla H, Karmen C, Bruckner T et al (2018) Tocolysis with the β2-sympathomimetic fenoterol does not increase the occurrence of infantile hemangioma in preterm and term infants. Arch Gynecol Obstet 10:S2–7. https://doi.org/10.1007/s00404-018-4830-5 CrossRef

27.

Boghossian NS, Saha S, Bell EF et al (2019) Birth weight discordance in very low birth weight twins: mortality, morbidity, and neurodevelopment. J Perinatol 206:10. https://doi.org/10.1038/s41372-019-0427-5 CrossRef

28.

Gur Z, Tsumi E, Wainstock T et al (2018) Association between delivery of small-for-gestational age neonate and long-term pediatric ophthalmic morbidity. Arch Gynecol Obstet 298:1095–1099. https://doi.org/10.1007/s00404-018-4901-7 CrossRefPubMed

29.

Ricard CA, Dammann CEL, Dammann O (2017) Screening tool for early postnatal prediction of retinopathy of prematurity in preterm newborns (STEP-ROP). Neonatology 112:130–136. https://doi.org/10.1159/000464459 CrossRefPubMed

30.

Cayabyab R, Ramanathan R (2016) Retinopathy of prematurity: therapeutic strategies based on pathophysiology. Neonatology 109:369–376. https://doi.org/10.1159/000444901 CrossRefPubMed

31.

Bizzarro MJ, Hussain N, Jonsson B et al (2006) Genetic susceptibility to retinopathy of prematurity. Pediatrics 118:1858–1863. https://doi.org/10.1542/peds.2006-1088 CrossRefPubMed

32.

Husain SM, Sinha AK, Bunce C et al (2013) Relationships between maternal ethnicity, gestational age, birth weight, weight gain, and severe retinopathy of prematurity. J Pediatr 163:67–72. https://doi.org/10.1016/j.jpeds.2012.12.038 CrossRefPubMed

33.

Mohamed S, Schaa K, Cooper ME et al (2009) Genetic contributions to the development of retinopathy of prematurity. Pediatr Res 65:193–197. https://doi.org/10.1203/PDR.0b013e31818d1dbd CrossRefPubMedPubMedCentral

34.

Movsas TZ, Spitzer AR, Gewolb IH (2015) Trisomy 21 and risk of retinopathy of prematurity. Pediatrics 136:e441–e447. https://doi.org/10.1542/peds.2015-0623 CrossRefPubMed

35.

Palmer EA, Flynn JT, Hardy RJ et al (1991) Incidence and early course of retinopathy of prematurity. The cryotherapy for retinopathy of prematurity cooperative group. Ophthalmology 98:1628–1640. https://doi.org/10.1016/s0161-6420(91)32074-8 CrossRefPubMed

36.

Léauté-Labrèze C, Dumas de la Roque E, Hubiche T et al (2008) Propranolol for severe hemangiomas of infancy. N Engl J Med 358:2649–2651. https://doi.org/10.1056/NEJMc0708819 CrossRefPubMed

37.

Bührer C, Bassler D (2015) Oral propranolol: a new treatment for infants with retinopathy of prematurity? Neonatology 108:49–52. https://doi.org/10.1159/000381659 CrossRefPubMed

38.

Praveen V, Vidavalur R, Rosenkrantz TS, Hussain N (2009) Infantile hemangiomas and retinopathy of prematurity: possible association. Pediatrics 123:e484–e489. https://doi.org/10.1542/peds.2007-0803 CrossRefPubMed

Title: Antenatal exposure to fenoterol is not associated with the development of retinopathy of prematurity in infants born before 32 weeks of gestation
Authors: Hannes Hudalla
Thomas Bruckner
Johannes Pöschl
Thomas Strowitzki
Ruben-J. Kuon
Publication date: 01-03-2020
Publisher: Springer Berlin Heidelberg
Keywords: Fenoterol
Infantile Hemangioma
Infantile Hemangioma
Published in: Archives of Gynecology and Obstetrics / Issue 3/2020
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-020-05463-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Antenatal exposure to fenoterol is not associated with the development of retinopathy of prematurity in infants born before 32 weeks of gestation

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

microRNA-141 inhibits TGF-β1-induced epithelial-to-mesenchymal transition through inhibition of the TGF-β1/SMAD2 signalling pathway in endometriosis

Placenta percreta evaluated by MRI: correlation with maternal morbidity

Sentinel lymph node mapping with fluorescent and radioactive tracers in vulvar cancer patients

Caesarean myomectomy of a large cervical fibroid

The impact of p16ink4a positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study

A meta-analysis of the effects of intramuscular and intravenous injection of oxytocin on the third stage of labor